Hansoh Pharma Reports Outstanding 2025 Financial Results, Demonstrating Strong Growth Driven by Innovation

On March 29, Hansoh Pharma (03692.HK) released its 2025 performance report. Driven by innovation and global strategic layout, the company achieved comprehensive and robust growth, with outstanding core operating indicators, demonstrating the strong development momentum and core competitiveness of a leading innovative pharmaceutical enterprise, setting a benchmark for high-quality development in China's innovative pharmaceuticals industry.

Report Shows Hansoh Pharma Achieves Leapfrog Growth in Core Operating Indicators by 2025, with Total Revenue, Profit, and R&D Expenditure Continuing Strong Momentum

Innovation-driven growth is the core engine of the company's strong expansion and the key support for breakthrough performance. Over the past year, the revenue from Hansoh Pharma's innovative drugs and collaborative products has maintained rapid growth, accounting for 82.2% of total revenue, becoming the central force driving robust performance growth. Over the past three years, Hansoh Pharma has consistently strengthened its innovative R&D efforts, with revenue from innovative drugs and collaborative products, as well as key operating metrics, maintaining high growth. The significant results of its innovation transformation have enabled the company to fully enter a new phase of innovation-driven development.

From the perspective of business segments, Hansoh Pharma's diversified layout highlights its advantages, with four core areas working in synergy and achieving breakthroughs at multiple points, building a strong business growth matrix. Among them, the oncology field serves as the core growth driver, generating revenue of 9.974 billion yuan in 2025, accounting for 66.4% of total revenue. Two key products, Almonertinib (Almele) and Flumatinib (Hansoh Xinfu), form a dual-driving pattern. Almonertinib (Amele, Methylate Almonertinib Tablets), as the core oncology product, has gained several new indications within the year, bringing the total number of approved indications to five. It has become the Chinese-developed third-generation EGFR-TKI with the broadest range of approved indications in China, with related research data being selected for authoritative international academic conferences, further solidifying its position in evidence-based medicine. Flumatinib (Hansoh Xinfu, Methylate Flumatinib Tablets) continues to strengthen its leading position in the treatment of chronic myeloid leukemia, expanding its market share through differentiated clinical value while driving continuous breakthroughs in related academic research achievements.

In addition to the anti-tumor field, Hansoh Pharma has also shown outstanding performance in the fields of central nervous system, anti-infective, and metabolic diseases. In the central nervous system field, Xin Yue (Inebilizumab Injection) has added two new indications for rare diseases, further broadening the treatment scope and consolidating the company's leading position in the rare disease sector. In the anti-infective field, Hengmu (Aimtinovir Tablets), as China’s first domestically developed oral anti-hepatitis B virus drug, has been recommended by 16 authoritative guidelines due to its clear clinical advantages, becoming one of the preferred solutions for chronic hepatitis B treatment. In the field of metabolism and others, products such as Fulai Mei (Polyethylene Glycol Loosenatide Injection) and Shengluolai (Pegmoceptin Injection) continue to gain market traction with increasing recognition, injecting new vitality into the company’s revenue growth.

Continuous investment in R&D has provided a solid foundation for the robust growth of Hansoh Pharma. Hansoh Pharma has always regarded innovation in R&D as its core strategy. In 2025, R&D expenditure accounted for a significant proportion of total revenue, with over 2,300 professional R&D personnel. Throughout the year, eight innovative drug candidates entered clinical trials for the first time, covering cutting-edge fields such as ADC and bispecific antibodies. Meanwhile, seven pivotal Phase III clinical trials were advanced, with all core R&D products achieving phased breakthroughs, laying a strong groundwork for future growth.

The continuous deepening of globalization has further amplified Hansoh Pharma's growth advantages. In 2025, Hansoh Pharma completed three major overseas licensing deals with a total transaction value exceeding $4.5 billion, covering cutting-edge fields such as GLP-1 and ADC. The collaborators include top global pharmaceutical companies, showcasing the international competitiveness of China's innovative drugs. Among them, the core product Almonertinib successfully entered the UK and EU markets, becoming the first China-developed EGFR-TKI to be launched overseas, driving China's innovative drugs onto the global stage.

Financially, Hansoh Pharma achieved a net cash inflow from operating activities of 6.738 billion yuan in 2025, with a year-end cash and bank deposit balance of 31.549 billion yuan. The robust cash flow strongly supports R&D investment, global expansion, and the transformation of research outcomes, further solidifying the company’s position in the industry.

In the field of sustainable development, Hansoh Pharma has also shown outstanding performance, with its MSCI ESG rating upgraded to AAA. All key indicators have reached leading levels in the global industry. The company’s practices in corporate governance, green development, and inclusive healthcare have gained international authoritative recognition, achieving the coordinated development of commercial value and social value.

Industry insiders said that Hansoh Pharma's performance in 2025 fully demonstrates its core advantages in innovative R&D, global layout, and product implementation. As a benchmark for innovative pharmaceutical companies in China, its continuous strong growth not only drives its own high-quality development but also leads the Chinese innovative pharmaceuticals industry to a higher level, injecting strong momentum into the international development of China's pharmaceuticals industry.